Novavax, Inc. (NVAX) Still Has Attractive Upside Potential?

Novavax, Inc. (NASDAQ:NVAX) is at least 60% than its current record low price of $1.15. There was a 0% decline on 12/31/2018 that led the price to move at $1.84. At recent session, the prices were hovering between $1.8 and $1.92. This company shares are 135.33% off its target price of $4.33 and the current market capitalization stands at $773.65M. The recent change has given its price a -4.52% deficit over SMA 50 and -33.09% deficit over its 52-week high. The stock witnessed -7.54% declines, -2.13% declines and 37.31% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found NVAX’s volatility during a week at 9.58% and during a month it has been found around 8.77%.

Novavax, Inc. (NVAX) Top Holders

Institutional investors currently hold around $290 million or 42.1% in NVAX stock. Look at its top three institutional owners. Blackrock Inc. owns $59.29 million in Novavax, Inc., which represents roughly 7.66% of the company’s market cap and approximately 20.44% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 22,331,455 shares of the stock are valued at $41.09 million. The third largest holder is State Street Corp, which currently holds $31.98 million worth of this stock and that ownership represents nearly 4.13% of its market capitalization.

Novavax, Inc. 13F Filings

At the end of September reporting period, 63 institutional holders increased their position in Novavax, Inc. (NASDAQ:NVAX) by some 17,270,874 shares, 63 decreased positions by 22,162,979 and 51 held positions by 118,116,138. That puts total institutional holdings at 157,549,991 shares, according to SEC filings. The stock grabbed 25 new institutional investments totaling 9,212,598 shares while 17 institutional investors sold out their entire positions totaling 9,130,531 shares.

Novavax, Inc. (NASDAQ:NVAX) Insider Trades

Multiple company employees have indulged in significant insider trading. Novavax, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President, R&D Glenn Gregory M has acquired 13,007 shares of Novavax, Inc. (NVAX) in trading session dated Jul. 31, 2018. These shares are worth $11,446 and were traded at $0.88 each. The SEC filing shows that Erck Stanley C performed a purchase of 100,000 shares. The President and CEO added these shares by way of transaction on May. 14, 2018. The company’s shares were assimilated at $1.65 per share worth to an investment of some $165,000 on account of Erck Stanley C.

SVP, CBO and CFO, Trizzino John, purchased 50,000 common shares of Novavax, Inc. (NVAX) in the open market. In a transaction dated May. 14, 2018, the shares were bought at an average price of $1.64, giving away a sum of $82,000. After this purchase, 138,965 common shares of NVAX are directly owned by the insider, with total stake valued at $255,696.

In the transaction dated May. 14, 2018, the great number of shares acquired came courtesy the President, R&D; Glenn Gregory M added a total of 20,000 shares at an average price of $1.64, amounting to approximately $32,800. The insider now directly owns 47,211 shares worth $86,868.

Novavax, Inc. (NVAX) Analyst Guide

Several analysts have released their opinion on Novavax, Inc. (NASDAQ:NVAX), with 3 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.88 average brokerage recommendation.